Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-01T11:15:01.924Z Has data issue: false hasContentIssue false

Levothyroxine supplementation among individuals with Subclinical Hypothyroidism and Depression | a review

Published online by Cambridge University Press:  01 September 2022

M. Ribeiro*
Affiliation:
Centro Hospitalar Lisboa Norte, Psychiatry, Lisboa, Portugal
A. Lourenço
Affiliation:
Centro Hospitalar Lisboa Norte, Psychiatry, Lisboa, Portugal
M. Lemos
Affiliation:
Centro Hospitalar Lisboa Norte, Psychiatry, Lisboa, Portugal
A. Duarte
Affiliation:
Centro Hospitalar Lisboa Norte, Psychiatry, Lisboa, Portugal
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depression is known to be associated with changes in the hypothalamic-pituitary-thyroid axis and the brain is a major target organ for thyroid hormone. Overt hypothyroidism can cause symptoms compatible with depression. However, its relationship with subclinical hypothyroidism (SCH) is not well established.

Objectives

To review the literature regarding the effect of levothyroxine therapy among patients with SCH and coexistent depression.

Methods

We conducted a MEDLINE search using depression, subclinical hypothyroidism and levothyroxine as keywords, selecting studies written in English.

Results

SCH is defined as an elevated thyroid stimulating hormone with normal peripheric hormone levels. The association between SCH and depression is controversial. Some studies indicate that SCH had the same propensity with overt hypothyroidism, while others report that major affective symptoms are not associated with SCH, but are likely due to independent psychiatric diagnoses, which are common in the general population and occur with similar frequency in patients with SCH. Individuals with SCH are recommended to initiate levothyroxine replacement therapy only when their TSH level is above 10 mIU/L or if symptoms are present. There is a lack of evidence supporting the use of levothyroxine therapy to improve mental health outcomes and the majority of meta-analysis do not show relief of affective symptoms after levothyroxine therapy, among individuals with SCH.

Conclusions

Routine screening for depressive symptoms among individuals with SCH is important to prevent morbidity. Nevertheless, there is no evidence enduring levothyroxine supplementation in these cases. Further studies, with larger sample sizes and longer follow-up periods are needed to enlighten the potential benefit of this therapy.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.